10 Toi M, Imoto S, Ishida T, et al. Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021...
In the case of advanced disease where two other drugs have been tried, the antibody-drug conjugatesacituzumab govitecan(Trodelvy) may be tried. Get an overview ontriple-negative breast cancer symptoms and treatment.
Influence of clinical, societal, and treatment variables on racial differences in ER-/PR- breast cancer survivalHormone receptor negative breast cancerAfrican AmericansSurvivalSocioeconomic statusRacial disparitiesBACKGROUND: African American (AA) women with breast cancer have persistently higher mortality ...
在HER3靶点方面,HER3-DXd在HER2阴性乳腺癌也有应用前景,例如此次ESMO-BC报道的ICARUS-BREAST01研究显示,3个月HER3-DXd治疗HR+/HER2-或HER2低表达患者,56例患者中,有16例(28.6%)PR和30例(53.6%)SD[11],既往1/2期U31402-A-J10...
[9]Bardia A, et al. Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple-Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study. 2022 ASCO. P6-10-03. [10]Schmid P, et al. Dato-DXd + durvalumab as 1L treatment for unresectable locally a/mTNBC: ...
2.3免疫组织化学 用免疫组织化学法检测ER/PR/HER2进行初步分子分型,ER/PR阴性且HER2免疫组织化学为2+者再用荧光原位杂交(fluorescence in situ hybridisation,FISH)检测有无HER2基因扩增,无基因扩增者纳入三阴(triple negative, TN)型,否则为HER2型。其中18例为TN型,11例为HER2型,4例归入其他类型。
Ruta D. Rao, MD, and Virginia G. Kaklamani, MD, discuss with participants the case of a patient with breast cancer who has received multiple lines of therapy and what the next steps are for her treatment. CASE SUMMARY Initial presentation: A 56-year-old, postmenopausal woman presented ...
Nineteen ER/PR-negative breast cancer survivors with a mean age of 59 years participated in the study. All but two of the participants completed the 12-week intervention. Women lost an average of 6.3 卤 4.9 kg (P < 0.001), equivalent to 7.5% of their baseline weight. There were ...
ER、PR、HER-2、Ki67在乳腺癌中的表达及其临床意义Expressions and Clinical Significances of ER,PR,HER-2 and Ki67 in Breast Cancer 李帆 - 《医学综述》 被引量: 0发表: 0年 Male Breast Carcinoma: Correlation of ER, PR, Ki-67, Her2-Neu, and p53 with Treatment and Survival, a Study of 65...
aKinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer. Kinome描出显露乳腺癌非均匀性并且辨认被瞄准的治疗机会为三倍消极乳腺癌。 [translate] aMinor Out Diameter 未成年人直径 [translate] aEvaluation of ER, PR and HER-2 ...